Votrient (pazopanib) — United Healthcare

Initial criteria

• Diagnosis of Merkel Cell Carcinoma AND disease is M1 disseminated AND (anti-PD-L1 or anti-PD-1 therapy is contraindicated OR disease has progressed on anti-PD-L1 or anti-PD-1 therapy)

Reauthorization criteria

• Patient does not show evidence of progressive disease while on Votrient therapy

Approval duration

12 months